EMA Authorised: Tegsedi (inotersen sodium) — Akcea Therapeutics Ireland Limited

View source ↗

Summary

EMA authorises Tegsedi (inotersen sodium) for amyloidosis, with orphan medicine designation and accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• TEGSEDI (inotersen)

Snippet

Status: Authorised. Therapeutic area: Amyloidosis. MAH: Akcea Therapeutics Ireland Limited. Decision date: 30/11/2023. Orphan medicine. Accelerated assessment